199 related articles for article (PubMed ID: 24677636)
1. Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.
Scherer D; Koepl LM; Poole EM; Balavarca Y; Xiao L; Baron JA; Hsu L; Coghill AE; Campbell PT; Kleinstein SE; Figueiredo JC; Lampe JW; Buck K; Potter JD; Kulmacz RJ; Jenkins MA; Hopper JL; Win AK; Newcomb PA; Ulrich CM; Makar KW
Genes Chromosomes Cancer; 2014 Jul; 53(7):568-78. PubMed ID: 24677636
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
[TBL] [Abstract][Full Text] [Related]
3. Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.
Samowitz WS; Wolff RK; Curtin K; Sweeney C; Ma KN; Andersen K; Levin TR; Slattery ML
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):894-901. PubMed ID: 16797247
[TBL] [Abstract][Full Text] [Related]
4. The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.
Angstadt AY; Hartman TJ; Lesko SM; Muscat JE; Zhu J; Gallagher CJ; Lazarus P
Genes Chromosomes Cancer; 2014 Jun; 53(6):454-66. PubMed ID: 24822274
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge M; Armitage N; Shepherd V; Popat S; Houlston RS;
Clin Cancer Res; 2006 Nov; 12(21):6585-9. PubMed ID: 17085674
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry.
Resler AJ; Makar KW; Heath L; Whitton J; Potter JD; Poole EM; Habermann N; Scherer D; Duggan D; Wang H; Lindor NM; Passarelli MN; Baron JA; Newcomb PA; Le Marchand L; Ulrich CM
Carcinogenesis; 2014 Sep; 35(9):2121-6. PubMed ID: 24908683
[TBL] [Abstract][Full Text] [Related]
7. IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry.
Seufert BL; Poole EM; Whitton J; Xiao L; Makar KW; Campbell PT; Kulmacz RJ; Baron JA; Newcomb PA; Slattery ML; Potter JD; Ulrich CM
Carcinogenesis; 2013 Jan; 34(1):79-85. PubMed ID: 23002237
[TBL] [Abstract][Full Text] [Related]
8. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
McGreavey LE; Turner F; Smith G; Boylan K; Timothy Bishop D; Forman D; Roland Wolf C; Barrett JH;
Pharmacogenet Genomics; 2005 Oct; 15(10):713-21. PubMed ID: 16141797
[TBL] [Abstract][Full Text] [Related]
9. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk.
Thompson CL; Plummer SJ; Merkulova A; Cheng I; Tucker TC; Casey G; Li L
World J Gastroenterol; 2009 May; 15(18):2240-4. PubMed ID: 19437564
[TBL] [Abstract][Full Text] [Related]
10. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.
Nan H; Hutter CM; Lin Y; Jacobs EJ; Ulrich CM; White E; Baron JA; Berndt SI; Brenner H; Butterbach K; Caan BJ; Campbell PT; Carlson CS; Casey G; Chang-Claude J; Chanock SJ; Cotterchio M; Duggan D; Figueiredo JC; Fuchs CS; Giovannucci EL; Gong J; Haile RW; Harrison TA; Hayes RB; Hoffmeister M; Hopper JL; Hudson TJ; Jenkins MA; Jiao S; Lindor NM; Lemire M; Le Marchand L; Newcomb PA; Ogino S; Pflugeisen BM; Potter JD; Qu C; Rosse SA; Rudolph A; Schoen RE; Schumacher FR; Seminara D; Slattery ML; Thibodeau SN; Thomas F; Thornquist M; Warnick GS; Zanke BW; Gauderman WJ; Peters U; Hsu L; Chan AT; ;
JAMA; 2015 Mar; 313(11):1133-42. PubMed ID: 25781442
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.
Kleinstein SE; Heath L; Makar KW; Poole EM; Seufert BL; Slattery ML; Xiao L; Duggan DJ; Hsu L; Curtin K; Koepl L; Muehling J; Taverna D; Caan BJ; Carlson CS; Potter JD; Ulrich CM
Genes Chromosomes Cancer; 2013 May; 52(5):437-49. PubMed ID: 23404351
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Pharmacogenet Genomics; 2009 Feb; 19(2):113-20. PubMed ID: 19077918
[TBL] [Abstract][Full Text] [Related]
13. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway.
Slattery ML; Samowitz W; Hoffman M; Ma KN; Levin TR; Neuhausen S
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):538-45. PubMed ID: 15066917
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
Chan AT; Tranah GJ; Giovannucci EL; Hunter DJ; Fuchs CS
J Natl Cancer Inst; 2005 Mar; 97(6):457-60. PubMed ID: 15770010
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in UDP-glucuronosyltransferase 1A6 are not associated with NSAIDs-related peptic ulcer haemorrhage.
van Oijen MG; Koetsier MI; Laheij RJ; Roelofs HM; te Morsche RH; Peters WH; Verheugt FW; Jansen JB; Drenth JP
Drug Metab Lett; 2009 Aug; 3(3):199-204. PubMed ID: 19799547
[TBL] [Abstract][Full Text] [Related]
16. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study.
Mallah N; Zapata-Cachafeiro M; Aguirre C; Ibarra-García E; Palacios-Zabalza I; Macías-García F; Piñeiro-Lamas M; Ibáñez L; Vidal X; Vendrell L; Martin-Arias L; Sáinz-Gil M; Velasco-González V; Bacariza-Cortiñas M; Salgado A; Estany-Gestal A; Figueiras A;
Ann Med; 2022 Dec; 54(1):379-392. PubMed ID: 35114859
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta.
Siezen CL; Tijhuis MJ; Kram NR; van Soest EM; de Jong DJ; Fodde R; van Kranen HJ; Kampman E
Pharmacogenet Genomics; 2006 Jan; 16(1):43-50. PubMed ID: 16344721
[TBL] [Abstract][Full Text] [Related]
18. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
[TBL] [Abstract][Full Text] [Related]
19. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain.
Fortuny J; Kogevinas M; Garcia-Closas M; Real FX; Tardón A; Garcia-Closas R; Serra C; Carrato A; Lloreta J; Rothman N; Villanueva C; Dosemeci M; Malats N; Silverman D
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1696-702. PubMed ID: 16985032
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):502-8. PubMed ID: 16537708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
